IsoRay's Cesium-131 And Surgical Resection Shows Promise In Recurrent Head & Neck Cancer

According to a recently published small pilot study of patients with recurrent head and neck cancers treated with surgical resection and IsoRay Inc's ISR, Cesium-131 brachytherapy showed potential benefits that could support further research into combination therapy.
This study's primary findings include the fact that re-treatment of recurrent head and neck cancers with surgical resection and Cesium-131 brachytherapy appears safe and feasible.
Study authors noted that brachytherapy provides the possibility of optimal dose conformity with sharp dose fall-off that limits radiation dose to normal tissues, leading to fewer side effects compared to external beam radiation therapy.
It was also noted that brachytherapy performed at the time of surgery is convenient for patients who would otherwise require 4-6 weeks of wound healing followed by 6-7 weeks of daily treatment with external beam radiation therapy.
Additionally, an acceptable rate of cancer recurrence inside the field of the Cesium-131 implant area was observed – one out of twelve and was distant to the area of the Cesium-131 implant.
The overall survival in this small series of patients was similar to those treated with a prolonged course of external beam radiation therapy.
Price Action: ISR shares are up 2.8% at $1.11 in the premarket session on the last check Wednesday.